Introduction
Selective inhibitors of factor Xa and thrombin are in clinical development for the prevention and treatment of thrombosis 1 . There are many practical advantages to an antithrombotic that can be taken in a fixed dosage and that does not require control of its effect. Therefore, trials that show that direct inhibitors of thrombin or factor Xa (FXa), when given in fixed doses, are not inferior to adjusted dose treatment with vitamin K antagonists (VKA) are hailed with enthusiasm [2] [3] [4] [5] .
Bleeding and thrombosis in patients under anticoagulant treatment have a local cause and are further determined by the coagulability of the blood, i.e. by the systematic component that determines the response to the local cause. There is a large body of evidence that the thrombin generating capacity of the plasma is an important element in this systematic component and that it is the function that is diminished by antithrombotics 6, 7 . The effect of antithrombotic treatment therefore is likely due to its effect on the thrombin generating capacity of blood. This determines the therapeutic results of the treatment, which are measured as the rates of thrombosis and bleeding in the treated group in comparison to a reference group.
The anticoagulant effect itself is a combination of how much of the drug reaches the target organ, i.e. the plasma (pharmacokinetics) and how the function of the target organ, i.e. the coagulability of plasma, is influenced by the drug (pharmacodynamics).
The pharmacokinetics of the new drugs have been reported to be predictable and stable [8] [9] [10] . For a fixed dose treatment to be safe and effective one would like the pharmacodynamic response to be predictable and stable within the population as well. We therefore measured the response of thrombin generation to a fixed concentration of different anticoagulants in a series of individual normal plasmas (n = 44). We tested unfractionated heparin (UFH) known to enhance the antithrombin and anti-factor Xa activity of plasmatic antithrombin 11 ; dermatan sulfate that enhances the anti-thrombin activity of heparin cofactor II 12 ; pentasaccharide that specifically enhances the 4 anti-factor Xa action of plasmatic antithrombin 13 ; otamixaban, a direct and reversible inhibitor of FXa 14 and melagatran, a direct and reversible inhibitor of thrombin 15 . Of each of these drugs we used a concentration that inhibits around 50% of either the thrombin generation peak or the endogenous thrombin potential (ETP: area under the thrombin generation curve).
Design and Methods

Preparation of platelet poor plasma
Blood was acquired from apparently healthy subjects through antecubital venipuncture and was collected into BD vacutainer tubes (1 volume trisodium citrate 0.105 M to 9 volumes blood) in the absence of corn trypsin inhibitor (BD Vacutainer System, Roborough, Plymouth, UK).
Platelet poor plasma (PPP) was obtained by centrifuging the blood at 2,900 g during 10 min at room temperature. Plasma was aspirated and the procedure was repeated. Aliquots of 2 ml were made and stored at -80°C until use.
PPP of the 44 individual donors was pooled (equal volumes of each donor) and will be referred to as 'Pool' throughout the study. Normal pooled plasma (NPP) was prepared, previously, as described above from at least 24 apparently healthy donors, different from those already mentioned and is used as a reference plasma. All enrolled volunteers gave their full informed consent according to the Helsinki Declaration and later Amendments and the study fulfilled all the institutional ethic requirements and was approved by the Medical Ethical Committee of the Maastricht University Medical Centre. 
Reagents
Synthetic procoagulant phospholipids (PL) were obtained from Avanti Polar Lipids Inc.
(Alabaster, AL, USA) and added in the form of vesicles consisting of phosphatidylserine, phosphatidylethanolamine and phosphatidylcholine, 1:1:3, mol:mol. Recombinant tissue factor (rTF) was Innovin (Dade-Behring, Marburg, Germany). The fluorogenic substrate Z-Gly-GlyArg-aminomethylcoumarine (ZGGR-AMC) was purchased from Bachem (Basel, Switzerland).
Calibrator was prepared according to Hemker et al. 16 . Hepes buffers containing 5 mg/ml or 60 mg/ml bovine serum albumin (BSA5 and 60, respectively) were prepared as described previously 17 . 
Calibrated A utomated Thrombinography
Calibrated automated thrombinography (CAT) was performed as described previously by Hemker et al. 16 . 10 µl of tissue factor/phospholipid mixture in BSA5 buffer was added to a well with 10 µl of BSA5 buffer with or without the anticoagulant (anticoagulants were not added to calibrator wells). Final concentrations of rTF and PL were 5 pM and 4 µM, respectively.
Thrombin generation was initiated by adding 20 µl of ZGGR-AMC (2.5 mM) and CaCl 2 (100 6 mM) in BSA60 buffer. NPP served as a control in each measurement. All experiments were performed in triplicate and the pre-warmed plate was placed in the fluorometer at 37°C for 10 min before initializing the measurement.
Experiments were constructed in such a manner as to measure the effect of all the different anticoagulants on the PPP of one (or more) donor(s) in one run. The experimental error in TG without any addition, as determined in NPP under these conditions, was 6.5% for the ETP and 4.7% for the peak (n = 37). The experimental error after addition of an anticoagulant to NPP was calculated with data of 14 measurements.
The thrombin generation curves and their parameters were derived from the fluorescence curves using the dedicated software provided with the CAT method (Thrombinoscope BV, Maastricht, the Netherlands).
A nticoagulant concentrations
Dose-response curves were constructed in order to select the IC 50 concentrations for each anticoagulant. However, the parameters of the CAT assay (ETP, peak height, time to peak and lag time) were affected diversely, which made it incompatible to compare the effects of the different agents by considering only one parameter. Since the ETP and peak height were the most informative parameters, we chose a fixed concentration of the anticoagulants where the sum of the inhibitions of ETP and peak was between 80 and 120%. Consequently, the following concentrations were utilized: otamixaban 200 nM; melagatran 400 nM, dermatan sulfate 20 µg/ml, pentasaccharide 0.9 µg/ml, UFH 0.08 U/ml (with around 30% high-affinity material 18 ).
The concentrations of the new anticoagulants used here are comparable to plasma concentrations effective in-vivo. A study in healthy male subjects used predicted target concentrations of otamixaban of 100 ng/ml; i.e. about 210 nM (200 nM used here) 19 . For melagatran, the proposed therapeutic plasma concentration is < 500 nM, (400 nM used here) 15 . Therapeutic doses of fondaparinux lead to a concentration of approximately 1.4 µg/ml 20 . The concentration of pentasaccharide in the present study is lower on purpose, because the aim was not to measure within the plateau region, which would obscure inter-individual differences.
Data analysis
To quantify the variability of the inhibitory effect of the different antithrombotics within the population of 44 normal plasmas we used the coefficient of variation (CV), i.e. the standard deviation expressed as a percentage of the average. The total CV is caused by random experimental error (CV error ) and by the inter-individual variation (CV ii ). The experimental error was derived from the measurements in NPP, which served as a reference plasma during each run.
The coefficient of inter-individual variation was calculated as:
CV ii = square root (CV total 2 -CV error 2 ) 21 .
The same formula was used to calculate the variation in susceptibility to inhibition (CV susc , i.e.
how much extra variation is induced by adding an anticoagulant) from the total CV of ETP and peak found in the absolute values of the inhibited (CV inh ) plasmas and in the uninhibited plasmas (CV uninh ):
The inhibition in thrombin generating capacity was calculated as follows: 100-((ETP after addition of an anticoagulant/ ETP before addition of an anticoagulant) x 100).
Results
Inhibition of normal pooled plasma
Important qualitative differences in the type of inhibition were observed ( Figure 1 ). The direct inhibitors (otamixaban, melagatran) have a stronger effect on the lag time than the heparin (-likes). Inhibition of factor Xa (otamixaban, pentasaccharide) primarily affects the peak and tends to protract thrombin generation so that the ETP is much less affected than the peak. In order to find concentrations that caused around 50% inhibition, we made dose-response curves in normal pooled plasma ( Figure 2 ). Inhibition of factor Xa systematically inhibits the peak more than the ETP, inhibition of thrombin affects both to a similar extent, UFH takes an intermediate position.
Because of these differences an unequivocal IC 50 could not be defined, as mentioned before, and arbitrarily we chose that concentration at which the sum of the inhibitions of ETP and peak was between 80 and 120%.
In order to determine the inter-assay CV of the TG, we tested the effect of the above-mentioned concentrations in normal pooled plasma in 14 fold. The inter-assay CV of the inhibition of the peak was 2-5%, except for UFH (8.5%). The CV of the inhibition of the ETP varied between 2 and 6%, yet otamixaban and pentasaccharide had a higher CV of 16 and 15%, respectively.
Inhibition of individual plasmas
The qualitative differences that were observed in normal pooled plasma were also seen in the individual plasmas. From Table 1 it is evident that the direct inhibitors have a strong effect on the lag time whereas the effect of those that require plasmatic cofactors is much less. Also the variation between individuals is between 18-30% after correction for experimental errors. Similar effects on time-to-peak were seen, with variations between 13 and 37% in inhibited plasmas and a CV of 14% in uninhibited plasma after correction for CV from experimental errors. after addition of anticoagulants.
Susceptibility to inhibition
The larger CV after inhibition compared to before suggests that the plasma of some individuals is more susceptible to inhibition than that of others. It might be possible that this susceptibility is dependent upon the activity of thrombin generation in the uninhibited plasma. We therefore investigated whether the degree of inhibition is dependent upon the value of uninhibited ("basal") thrombin generation, i.e. whether persons with a high basal thrombin generation would be more prone to inhibition than those with a lower one. Plots of the degree of inhibition against the basal ETP or peak did not show any consistent correlation (data not shown). It thus can be assumed that the variation in inhibition superimposes independently upon the variation of the basal values.
The variation in the susceptibility to the anticoagulants (i.e. how much extra variation is induced by the addition of the anticoagulant) was calculated from the variation in the absolute values obtained before and after inhibition. These values vary between 17.0 and 39.3% for peak height and between 2.3% and 16.2% for the ETP, without apparent differences between direct and heparin (-like) inhibitors (see Table 2 ). The variation is susceptibility was also calculated for the lag time, as indicated in Table 1 .
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The average inhibition by the anticoagulants was 25-68% for the ETP and 57-83% for peak height ( Table 3 ). The level of inhibition was also determined in the pool prepared from the 44 individual plasmas. It was comparable to the mean inhibition obtained from the 44 individual plasmas (within a range of 5%) for all anticoagulants, with the exception of pentasaccharide.
Discussion
In clinical trials, direct inhibitors of thrombin or of FXa are not inferior to traditional VKA prophylaxis [2] [3] [4] [5] . It has been surmised, however, that certain patients could benefit from dose adaptation 22, 23 . This raises the question whether dose adaptation should be restricted to certain categories or whether it could improve the results with direct inhibitors so as to become better than the -admittedly not ideal-results of VKA prophylaxis. This article deals with a partial problem pertaining to this question, viz. will the plasma of different persons react similarly to a fixed dose of antithrombotic?
We start from the a priori assumption -sustained by a wealth of literature 16, 20, [24] [25] [26] [27] [28] [29] [30] -that thrombin generation is a sensitive surrogate variable for bleeding-or thrombotic tendency. All known drugs that diminish thrombin generation have an antithrombotic action, independent of their mode of action. It therefore is a reasonable assumption that antithrombotic drugs, such as tested in this communication, act because they diminish thrombin generation and that therefore their action can be quantified by measuring to what degree they diminish it. Clotting times (aPTT, PT, lag time of thrombin generation), on the contrary, may or may not prolong, depending upon the nature of the antithrombotic agent and/or the condition of the assay 24, 31, 32 ( Figure 1 and Table 1 ).
It is known that the capacity to form thrombin varies widely between individuals. In a normal adult population the coefficient of variation is ~15% 16 . Our results show that adding a fixed amount of any anticoagulant causes a variable inhibitory effect with CVs of 6-48% for ETP and 3-23% for peak height, which adds to the variation already present in the population. The modern antithrombotics otamixaban, melagatran and pentasaccharide are indeed as variable as unfractionated heparin or dermatan sulfate are. From the literature it is known that low molecular weight heparins do no better either 20 .
There must exist a range of thrombin generation values that minimizes the risk of thrombosis without causing undue bleeding risk. What this "prophylactic window" is, cannot be answered with any accuracy at the moment. It only has been determined for VKA treatment, which however affects the protein C system as well as the procoagulant system 33 and therefore is not directly comparable to the materials tested here. After a first idiopathic venous thrombosis people with above average thrombin generation have a four times higher risk of recurrence than those below the average 34 . This would mean that moderate anticoagulation so as to result in thrombin generation below average would already have a beneficial effect.
The evident under limit is set by the risk of bleeding. Thrombin generation to below ~20% of normal, i.e. an ETP of below ~350 nM.min in congenital factor deficiencies is associated with a definite bleeding risk 35 , as is an international normalized ratio (INR) > 4 36 , which again corresponds to an ETP of ~300 nM.min. From this it follows that treatment which keeps a trial population under the average ETP of a normal population, i.e. 1800 nM.min 16 , and above the threshold limit for bleeding, i.e. an ETP > 300 nM.min, will show a beneficial effect. This is a very large window, which explains the positive outcome of clinical trials despite the large interindividual variation. An optimal beneficial effect, however, is to be expected within significantly shorter brackets. INR 2-3, which has been proven to be adequate in oral anticoagulation, corresponds roughly to an ETP in the range of 500-700 nM.min 37 . Due to the effect of VKAs on proteins S and C the optimal range for other antithrombotics may be situated at higher levels of the ETP, but there is no reason to assume that it would cover a wider range. The large variation of 12 the susceptibility of the target organ to inhibition, together with the variation in individual properties that influence the pharmacokinetics (e.g. weight) will in all probability not allow to keep a (trial) population within narrow limits of optimal prophylaxis unless the dose is tuned to the needs of the individual.
Previous studies have shown that variations in blood coagulation proteins varied from 50% to 150% of the mean values and can be associated with thrombotic events. However, the most important factors to affect thrombin generation are prothrombin and antithrombin [38] [39] [40] .
Our results are in accordance with previous work by Hacquard et al. on low molecular weight heparins (LMWH´s) that also showed inter-individual variances for the inhibition of ETP around 20% 20 . An earlier study was performed in our group to asses TG in healthy subjects who received fixed doses of UFH and LMWH´s. Variances in the inhibitory effect of 32% and 13-21% were found for UFH and LMWH´s, respectively 41 . A study performed by Freyburger et al. concluded also that there is a high inter-individual variability in response to dabigatran and rivaroxaban 42 . In the latter two studies also pharmacokinetic variation plays a role.
Looking at the results in more detail reveals some interesting observations.
• Inhibition of FXa by otamixaban, causes a strong inhibition of the peak but a significant protraction of the thrombin generation process, so that the ETP is much less inhibited than the peak. We surmise that this can be due to inhibition of the direct positive feedback action of FXa on FVII 43 , which will cause a prolongation of the lag time and a slow start of prothrombinase formation, together with inhibition of the negative feedback on the TF-FVIIa complex by the tissue factor pathway inhibitor (TFPI)-FXa complex which prevents shutting off of the extrinsic pathway.
• The inhibition by dermatan sulfate appears to reach a plateau rather than tending to complete inhibition. This may be due to the fact that there is less heparin cofactor II in the plasma (~ 1 µM) than prothrombin (~ 2 µM) so that even complete activation of heparin cofactor II by dermatan sulfate would not lead to complete inhibition of thrombin generation. This implies that it would be an antithrombotic that cannot be overdosed!
• The fact that dermatan sulfate and UFH only slightly prolong the lag time, in contrast to melagatran, indicates that the positive feedback mechanism of factor V activation by thrombin is only accessible to a direct inhibitor, probably because it is membrane-bound and involves meizothrombin rather than thrombin. A similar difference is seen between otamixaban and pentasaccharide. Probably, the feedback activation of factor VII by factor Xa is membrane-bound and therefore inaccessible to inhibition by the pentasaccharideantithrombin complex 44, 45 .
These two examples together show that the relation between lag time, (≈ clotting time) and thrombin generation is mechanism dependent, so that clotting time measurements cannot be used Our results suggest that the results of direct inhibitors could be improved by tuning the dose to the needs of the individual patient. Due to the large 'prophylactic window' fine tuning is probably not required; differentiation between high, middle and low responders might suffice.
However, further in vivo investigation into this facet is warranted. Since the CV ii after addition of otamixaban is lower than before, the CV susc cannot be calculated. ETP, endogenous thrombin potential; other abbreviations and details are as stated in Table 1 . Abbreviations and details are as stated in Table 1 
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